Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885786 | 0.93 | CNR2 (0.59) | CNR2TP53MAPTMAOAMAOB | |
| SCHEMBL3882211 | 0.92 | CNR2 (0.52) | CNR2TP53MAPTMAOAMAOB | |
| SCHEMBL3883904 | 0.91 | CNR2 (0.58) | CNR2TP53MAPTMAOAMAOB | |
| SCHEMBL4523179 | 0.91 | CNR2 (0.55) | CNR2TP53MAPTMAOAMAOB | |
| SCHEMBL4530045 | 0.90 | CNR2 (0.54) | CNR2TP53MAPTMAOAMAOB | |
| SCHEMBL3880173 | 0.89 | CNR2 (0.57) | CNR2TP53MAPTMAOAMAOB | |
| SCHEMBL3993825 | 0.89 | TP53 (0.59) | CNR2TP53MAPTMAOAMAOB | |
| SCHEMBL4042357 | 0.89 | CNR2 (0.54) | CNR2TP53MAPTMAOAMAOB | |
| SCHEMBL4520770 | 0.88 | MAOA (0.46) | CNR2TP53MAPTMAOAMAOB | |
| SCHEMBL3883027 | 0.88 | CNR2 (0.54) | CNR2TP53MAPTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | claimed |
| US-20090318546-A1 | Chromen-2-One Derivatives | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | claimed |
| EP-3723801-B9 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | BIORA THERAPEUTICS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3723801-B1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | BIORA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | GLAS USA LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | CYP1A2, CYP4B1, CYP1B1 | CNR2 538/4885TP53 487/4885MAPT 3872/4885 |
| US-20220135666-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR | S1PR2, S1PR1, S1PR4 | CNR2 136/4885TP53 3744/4885MAPT 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.